Drugs / Zolacabtagene- Autoleucel
Trials 8
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-10-25 | Bristol-Myers Squibb | Results Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025 bms.com ↗
Bristol Myers Squibb (NYSE: BMY) today announced updated data and first disclosure of results in chronic, refractory autoimmune diseases from the Phase 1 Breakfree-1 study (NCT05869955) of its investigational, autologous CD19-targeted NEX-T™ CAR T cell therapy BMS-986353 (CC-97540). |
| 2024-12-09 | Bristol-Myers Squibb | Results Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline bms.com ↗
Bristol Myers Squibb (NYSE: BMY) announced results from 18 presentations reinforcing its leadership in cell therapy, with data demonstrating efficacy, durability and safety of currently available therapies in blood cancers and highlighting the potential of its pipeline for future indications including autoimmune diseases. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-25 | Bristol-Myers Squibb | Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025 bms.com ↗ |
| 2024-12-09 | Bristol-Myers Squibb | Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline bms.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zolacabtagene- Autoleucel | “BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells” NCT07335562 ↗ |
| Known as | BMS-986353 | “Receive CC-97540 (BMS-986353) as part of the study” NCT07573332 ↗ |
| Known as | CC 97540 | “Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC 97540.” NCT04231747 ↗ |
| Known as | Zola-cel | “BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells” NCT07335562 ↗ |
| Modality | Cell therapy | “CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells” NCT04231747 ↗ |
| Route | Intravenous | “one dose of CC 97540 administered by intravenous (IV) injection” NCT04231747 ↗ |
| Target | CD19 | “CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells” NCT04231747 ↗ |